|Bid||0.00 x 800|
|Ask||0.00 x 1400|
|Day's Range||70.70 - 72.44|
|52 Week Range||60.42 - 75.11|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||73.25|
|Forward Dividend & Yield||0.66 (0.93%)|
|1y Target Est||N/A|
The expanded state-of-the-art facility incorporates recently acquired Luxcel Biosciences, adding real-time, fluorescence plate reader-based in vitro cell assay kits to Agilent’s cell analysis portfolio. The complex will house two new laboratories, one dedicated to cell analysis technologies, and the other to develop biosensors and related bio assay solutions. Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in the development of specialized instruments and live-cell, kinetic assays.
Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash. This acquisition brings together two pioneers in cellular function and metabolism measurements focused on real-time, live cell analyses. ACEA has developed two ground-breaking platforms that are complementary to Agilent’s current portfolio.
Agilent Technologies Inc. (NYSE:A) today announced that its board of directors has increased the company’s quarterly dividend to 16.4 cents per share of common stock. Agilent Technologies Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Align Technology, Inc. (“Align” or “the Company”) (NASDAQ: ALGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between July 25, 2018 and October 24, 2018, inclusive (the “Class Period”), are encouraged to contact the firm before January 4, 2019. We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.
Agilent Technologies Inc. (NYSE:A) today introduced the Cary 3500 UV-Vis system, an innovative spectrophotometer designed to help life science, pharma and biopharma research communities simplify their analyses, optimize laboratory productivity, and ultimately help bring new therapeutics to market faster. Agilent will showcase the Cary 3500 UV-Vis system at analytica China, being held October 31 – November 2, 2018, in Shanghai, China.
Agilent Technologies Inc. (NYSE:A) today announced the introduction of Agilent OnePGT, a genome-wide, next-generation sequencing (NGS) solution for preimplantation genetic testing (PGT). Agilent will showcase the OnePGT solution at the 5th Congress on Controversies in Preconception, Preimplantation and Prenatal Genetic Diagnosis (CoGEN), November 1-3, 2018 in Paris, France. This innovative solution provides fertility specialists the ability to more easily achieve comprehensive PGT data in which to support enhanced embryo ranking, identifying the best quality embryos for transfer.
NEW YORK, Oct. 31, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Agilent Technologies Inc. (NYSE:A) today announced that it sent a letter to the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC) regarding misstatements in the S-1 Registration Statement filed by Twist Bioscience Corp. Ms. Leproust admitted under oath that she secretly became Twist’s CEO 17 months prior to leaving Agilent.
Agilent Technologies Inc. (NYSE:A) is pleased to announce Eric Gerber as the company’s new senior vice president of strategy and corporate development, reporting to Agilent President and CEO, Mike McMullen, effective November 1, 2018. Gerber will lead the corporate development team in identifying, developing and evaluating M&A plans globally while collaborating with the businesses groups to help drive critical growth initiatives across the company.
Agilent Technologies Inc. (NYSE:A) today announced that it has been recognized by Forbes as one of the World’s Best Employers. This marks the second consecutive year that Agilent has been named to this elite global list. Agilent is ranked number 125 of the 500 companies on the list.
Agilent Technologies Inc. will release fourth-quarter fiscal 2018 financial results after the stock market closes on November 19. The company will host a live webcast of its investor conference call in listen-only mode.
NEW YORK, Oct. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Cell Analysis Just Got Better! ACEA Biosciences announced today that it has signed a definitive agreement to join Agilent Technologies, Inc. (NYSE:A). ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries.
Combined clinical reagent and instrument portfolio allows for optimized complete solutions. Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250 million in cash. “Expanding our cell analysis footprint is a key strategic growth initiative,” said Jacob Thaysen, president of Agilent’s Life Sciences and Applied Markets Group.
Agilent Technologies Inc. (NYSE:A) today announced that a quarterly dividend of 14.9 cents per share of common stock will be paid on October 24, 2018, to all shareholders of record as of the close of business on October 2, 2018. Agilent Technologies Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.
Agilent Technologies Inc. filed a new complaint against Twist Bioscience Corp. and Emily Leproust. The proposed Second Amended Complaint adds two additional defendants and adds new facts that were recently discovered regarding the defendants’ wide-ranging theft of Agilent’s proprietary oligonucleotide synthesis technology.
Agilent Technologies Inc. (NYSE:A) today announced that the winner of the 2018 Agilent Early Career Professor Award is Christoph Thaiss, Ph.D., assistant professor of microbiology in the Perelman School of Medicine at the University of Pennsylvania. Dr. Thaiss’s research focuses on the microbiome and how it mediates the response of its host to environmental cues, which strongly influences the organism’s health and disease states. “We are very happy to support Dr. Thaiss and his transformative microbiome research," said Jack Wenstrand, director of University Relations and External Research at Agilent.
Agilent Technologies Inc. (NYSE:A) today announced that it has been recognized as one of Aon’s Best Employers in Malaysia for 2018. Agilent received the honor from Aon at an award ceremony this week in Kuala Lumpur, Malaysia. Aon is a leading global professional services firm that provides a broad range of risk, retirement, and health solutions through its flagship program Aon Best Employers.
PD-L1 IHC 22C3 pharmDx Now Approved to Identify Certain Urothelial Carcinoma Patients for Treatment With KEYTRUDA®
Agilent Technologies Inc. (NYSE: A) today announced that it has completed its acquisition of the Agilent-related business from Young In Scientific Co. Ltd. and its affiliates (“YI Scientific”). YI Scientific is a leading distributor of analytical and scientific instruments in South Korea and a long-time distributor of Agilent instruments and services. Agilent and YI Scientific have enjoyed a strong partnership over many years.